{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:44:27Z","timestamp":1788515067685,"version":"build-2803163510"},"reference-count":63,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Classical Hodgkin lymphoma (cHL) is characterized by nearly universal genetic alterations in 9p24.1, resulting in constitutive expression of PD-1 ligands. This likely underlies the unique sensitivity of cHL to PD-1 blockade, with response rates of \u223c70% in relapsed\/refractory disease. There are now numerous clinical trials testing PD-1 inhibitors in earlier stages of treatment and in combination with many other therapies. In general, non-Hodgkin lymphomas (NHLs) do not display a high frequency of 9p24.1 alterations and do not share cHL\u2019s vulnerability to PD-1 blockade. However, a few entities have genetic or immunologic features that may predict sensitivity to immune checkpoint blockade. These include primary mediastinal B cell lymphoma, primary central nervous system lymphoma, and primary testicular lymphoma, which harbor frequent alterations in 9p24.1, as well as Epstein Barr virus (EBV)\u2013infected lymphomas, where EBV infection leads to increased PD-L1 expression. Although these subtypes may be specifically vulnerable to PD-1 blockade, the majority of NHLs appear to be minimally sensitive to PD-1 blockade monotherapy. Current investigations in NHL are therefore focusing on targeting other checkpoints or studying PD-1\u2013based combination therapy. Looking forward, additional insight into the most common mechanisms of resistance to immune checkpoint inhibitors will be important to guide rational clinical trial design. In this review, we describe the biological basis for checkpoint blockade in cHL and NHL and summarize the clinical data generated to date. Guided by our rapidly evolving understanding of the pathobiology of various lymphoma subtypes, we are hopeful that the role of checkpoint inhibitors in lymphoma treatment will continue to grow.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017012534","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T09:44:51Z","timestamp":1570700691000},"page":"2643-2654","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":92,"title":["Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"1","author":[{"given":"Reid W.","family":"Merryman","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T.","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"issue":"1","key":"2019111617264148200_B1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2019111617264148200_B2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett"},{"issue":"1","key":"2019111617264148200_B3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111617264148200_B4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"issue":"11","key":"2019111617264148200_B5","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/sj.emboj.7601146","article-title":"T-cell tolerance or function is determined by combinatorial costimulatory signals","volume":"25","author":"Nurieva","year":"2006","journal-title":"EMBO J"},{"issue":"7077","key":"2019111617264148200_B6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"8","key":"2019111617264148200_B7","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.4049\/jimmunol.179.8.5064","article-title":"PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues","volume":"179","author":"Keir","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"2019111617264148200_B8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"10","key":"2019111617264148200_B9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses","volume":"10","author":"Nishimura","year":"1998","journal-title":"Int Immunol"},{"issue":"1","key":"2019111617264148200_B10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"2019111617264148200_B11","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111617264148200_B12","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111617264148200_B13","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111617264148200_B14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111617264148200_B15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2019111617264148200_B16","first-page":"2420","article-title":"Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","author":"Carey","year":"2017"},{"issue":"9","key":"2019111617264148200_B17","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur J Immunol"},{"issue":"4","key":"2019111617264148200_B18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"issue":"1","key":"2019111617264148200_B19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"2019111617264148200_B20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"issue":"7655","key":"2019111617264148200_B21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"4","key":"2019111617264148200_B22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"2019111617264148200_B23","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111617264148200_B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1108.1108","article-title":"Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b Keynote-013 study [abstract]","volume":"128","author":"Armand","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111617264148200_B25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 2","key":"2019111617264148200_B26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hon.2437_124","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow-up of the phase 2 CHECKMATE 205 trial","volume":"35","author":"Fanale","year":"2017","journal-title":"Hematol Oncol"},{"issue":"19","key":"2019111617264148200_B27","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2019111617264148200_B28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hon.2437_125","article-title":"Pembrolizumab monotherapy in patients with primary refractory classical Hodgkin lymphoma: subgroup analysis of the phase 2 KEYNOTE-087 study","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"2019111617264148200_B29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"2019111617264148200_B30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111617264148200_B31","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039) [abstract]","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111617264148200_B32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hon.2437_73","article-title":"Interim results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"35","author":"Herrera","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 2","key":"2019111617264148200_B33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hon.2437_72","article-title":"Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed \/ refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412)","volume":"35","author":"Diefenbach","year":"2017","journal-title":"Hematol Oncol"},{"issue":"12","key":"2019111617264148200_B34","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"13","key":"2019111617264148200_B35","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111617264148200_B36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/gcc.22345","article-title":"Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies","volume":"55","author":"Van Roosbroeck","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"2019111617264148200_B37","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111617264148200_B38","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2011.116","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations","volume":"24","author":"Eberle","year":"2011","journal-title":"Mod Pathol"},{"issue":"6","key":"2019111617264148200_B39","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111617264148200_B40","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111617264148200_B41","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111617264148200_B42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111617264148200_B43","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum Pathol"},{"issue":"2","key":"2019111617264148200_B44","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J"},{"issue":"37","key":"2019111617264148200_B45","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"2019111617264148200_B46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111617264148200_B47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 blockade in mediastinal gray-zone lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111617264148200_B48","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2019111617264148200_B49","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2019111617264148200_B50","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111617264148200_B51","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"33","key":"2019111617264148200_B52","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2019111617264148200_B53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/hon.2437_126","article-title":"A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma (NHL)","volume":"35","author":"Palomba","year":"2017","journal-title":"Hematol Oncol"},{"issue":"3","key":"2019111617264148200_B54","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111617264148200_B55","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"issue":"23","key":"2019111617264148200_B56","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111617264148200_B57","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111617264148200_B58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111617264148200_B59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"2019111617264148200_B60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hon.2437_108","article-title":"High response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 2","key":"2019111617264148200_B61","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hon.2438_127","article-title":"A phase I study of utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in combination with rituximab in patients with CD20 + non-Hodgkin\u2019s lymphoma","volume":"35","author":"Gopal","year":"2017","journal-title":"Hematol Oncol"},{"issue":"17","key":"2019111617264148200_B62","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111617264148200_B63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.181.181","article-title":"Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and Sezary syndrome: clinical efficacy in a Citn multicenter phase 2 study [abstract]","volume":"128","author":"Khodadoust","year":"2016","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/26\/2643\/879987\/advances012534.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/26\/2643\/879987\/advances012534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T02:52:12Z","timestamp":1575859932000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/26\/2643\/16244\/Checkpoint-blockade-in-Hodgkin-and-nonHodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":63,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017012534","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]}}}